Latest News
Latest News
NY Nurse Practitioners Sue State Over Pay Equity, Alleged Gender Inequality
Lawsuit alleges that NPs in NY state are depended on, but not paid adequately for their work.
Latest News
Beyond Scope Creep: Why Physicians and PAs Should Come Together for Patients
AMA has sought to limit expansion of PA roles, but clinicians argue collaboration is needed improve care access.
Latest News
Lawsuit Targets Publishers: Is Peer Review Flawed?
Lawsuit alleges peer review processes slow publication; separate studies have found unethical practices.
Latest News
How AI Is Revolutionizing Drug Repurposing for Faster, Broader Impact
AI is accelerating the drug repurposing process, offering faster analysis of possible drug-disease matches.
From the Journals
Methotrexate in Preventing RA: Benefits in ACPA-Negative Patients, and Is It Cost Effective?
ACPA–negative individuals with clinically suspect arthralgia had reduced rates of RA development when treated with a 1-year course of methotrexate...
From the Journals
Frailty, Not Just Advanced Age, Affects ANCA Vasculitis Outcomes
Frailty emerged as an independent risk factor for severe infection and end-stage renal disease or death across different age groups in older...
Latest News
Why Residents Are Joining Unions in Droves
Residents are committed to fighting for their workplace rights — no matter how time-consuming or difficult its has been.
From the Journals
Crisugabalin Alleviates Postherpetic Neuralgia Symptoms in Phase 3 Study
“Crisugabalin 40 mg/d or crisugabalin 80 mg/d was well tolerated and significantly improved ADPS compared to placebo.”
From the Journals
Weight Loss After Anti-Obesity Medications Linked to Reduced Gout Risk
The 5-year risk for incident gout was the lowest among patients in the fast weight loss group.
Latest News
Surgical Center Wins $421 Million Verdict Against Blue Cross
Huge verdict for surgery center could signal more leverage for out-of-network providers to determine insurance payments.
News from the FDA/CDC
FDA Approves Ustekinumab Biosimilar Otulfi
This is the fourth ustekinumab biosimilar approved in the United States.